Last 43 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.22 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.29 | 25.84 | 31.64 | 7.58 | 58.87 | 22.86 | 269.86 | 116.17 | 2.88 | 15.69 | 16.96 | 3976.02 | 51.26 | 63.92 | 57.57 | 99.10 | 1.64 | 29.02 | 90.13 | 1035.92 | 3054.38 |
| — | +13.0% | -88.3% | -93.5% | +1946.4% | +45.7% | +1491.4% | -97.1% | -94.4% | -75.4% | -70.5% | +3912.2% | +3030.3% | +120.3% | -36.1% | -90.4% | -99.9% | +450.7% | +50.1% | +22214.0% | +19198.3% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | 23.56 | 6.38 | 3.67 | 3.50 | 4.34 | 4.43 | 19.99 | 14.54 | 8.29 | 15.34 |
| — | — | — | — | — | — | — | — | — | — | — | +443.1% | +44.0% | -81.7% | -75.9% | -47.7% | -71.1% | +124.5% | +24.7% | +13.8% | +39.2% | |
| P/FCF | — | — | — | — | — | — | — | — | 48.68 | — | — | — | — | — | — | 8.88 | 8.32 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.85 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.85 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.0% | 100.0% | 82.9% | 89.4% | 51.3% | 100.0% | 100.0% | 87.8% | 99.7% | 83.5% | 79.1% | 100.0% | 31.5% | 100.0% | 90.1% | 100.0% | 99.8% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | 0.0% | -17.1% | +1.7% | -48.5% | +19.8% | +26.5% | -12.2% | +216.3% | -16.5% | -12.2% | 0.0% | -68.4% | 0.0% | -9.9% | 0.0% | -0.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -1735.7% | -3502.5% | -725.2% | -223.4% | -2336.3% | -571.7% | -8433.3% | -3569.1% | -45.9% | -821.2% | -714.1% | -190125.0% | -2445.5% | -2527.8% | -2040.9% | -2203.5% | 72.8% | -159.0% | -781.5% | -24555.9% | -64636.4% |
| — | -512.7% | +91.4% | +93.7% | -4985.3% | +30.4% | -1080.9% | +98.1% | +98.1% | +67.5% | +65.0% | -8528.5% | -3457.9% | -1489.4% | -161.1% | +91.0% | +100.1% | -124.4% | +50.2% | -35374.4% | -41560.8% | |
| Net Margin | -2064.4% | -2971.1% | -913.6% | -352.9% | -2387.6% | -740.7% | -8437.8% | -5114.3% | -76.2% | -1078.8% | -894.5% | -232000.0% | -2928.2% | -2942.5% | -2034.6% | -2202.3% | 72.8% | -159.0% | -781.4% | -21620.6% | -64654.5% |
| — | -301.2% | +89.2% | +93.1% | -3035.2% | +31.3% | -843.3% | +97.8% | +97.4% | +63.3% | +56.0% | -10434.4% | -4120.3% | -1750.9% | -160.4% | +89.8% | +100.1% | -124.3% | +51.9% | -30329.2% | -40455.3% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | -139.5% | -66.3% | -35.7% | -27.4% | -21.9% | 67.0% | -26.3% | -33.6% | -57.1% | -84.2% |
| — | — | — | — | — | — | — | — | — | — | — | -535.9% | -198.9% | -36.0% | +18.2% | +61.6% | +179.6% | +16.8% | +48.3% | -111.8% | -184.5% | |
| ROA | -116.2% | -44.3% | -25.7% | -36.7% | -26.9% | -24.4% | -20.5% | -31.7% | -14.1% | -25.2% | -21.7% | -19.3% | -18.1% | -18.1% | -23.4% | -19.4% | 53.2% | -17.5% | -21.6% | -31.2% | -38.7% |
| — | -81.7% | -25.3% | -15.7% | -90.6% | +3.2% | +5.6% | -64.1% | +21.8% | -39.0% | +7.2% | +0.1% | -133.9% | -3.7% | -8.2% | +37.9% | +237.5% | -26.1% | +19.7% | -177.6% | -229.3% | |
| ROIC | — | — | — | — | — | -376.0% | — | — | — | — | — | — | — | — | — | -190.0% | 1867.0% | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | 0.45 | 3.32 | 1.74 | 0.02 | 0.02 | 0.02 | 0.04 | 0.04 | 0.05 | 0.23 |
| — | — | — | — | — | — | — | — | — | — | — | +2329.8% | +18602.7% | +4006.1% | -54.3% | -65.4% | -92.1% | -83.2% | -85.1% | -91.2% | -60.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.04 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.44 | 2.98 | 3.87 | 3.19 | 4.44 | 4.49 | 5.07 | 6.07 | 4.42 | 5.28 | 6.85 | 8.54 | 8.54 | 10.54 | 5.56 | 8.49 | 9.08 | 2.90 | 3.14 | 2.59 | 1.82 |
| — | -33.6% | -23.7% | -47.5% | +0.4% | -15.0% | -26.0% | -28.9% | -48.2% | -49.9% | +23.1% | +0.6% | -5.9% | +263.9% | +76.9% | +227.3% | +398.4% | +48.4% | +77.6% | +51.9% | -21.2% | |
| Quick Ratio | 4.44 | 2.98 | 3.87 | 3.19 | 4.44 | 4.49 | 5.07 | 6.07 | 4.42 | 5.28 | 6.85 | 8.54 | 8.54 | 10.54 | 5.56 | 8.49 | 8.88 | 2.90 | 3.14 | 2.59 | 1.82 |
| — | -33.6% | -23.7% | -47.5% | +0.4% | -15.0% | -26.0% | -28.9% | -48.2% | -49.9% | +23.1% | +0.6% | -3.8% | +263.9% | +76.9% | +227.3% | +387.5% | +48.4% | +77.6% | +51.9% | -21.2% | |
| Interest Coverage | -2.51 | -1.32 | -0.63 | -1.81 | -1.83 | -2.13 | -2.25 | -3.90 | -1.12 | -2.53 | -2.97 | -3.28 | -3.73 | -5.03 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 43 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLSD stock.
Clearside Biomedical, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Clearside Biomedical, Inc.'s current operating margin is -1735.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Clearside Biomedical, Inc.'s business trajectory between earnings reports.